Advertisment

Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:187

Official publication of the Indian Society of Nephrology
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4582    
    Printed91    
    Emailed0    
    PDF Downloaded110    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 CASE REPORT
Year : 2018  |  Volume : 28  |  Issue : 1  |  Page : 73-75

Eculizumab dosing in infants


1 Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
2 Department of Medicine, Division of Nephrology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
3 Department of Pediatrics; Departments of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University; Department of Children's Health and Therapeutics, Children's Health Research Institute, London, ON, Canada

Correspondence Address:
Dr. G Filler
Department of Pediatrics, Children's Hospital - London Health Sciences Centre, University of Western Ontario, 800 Commissioner's Road East, Rm B1-138A, London, ON N6A 5W9
Canada
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijn.IJN_310_16

Rights and Permissions

Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in infants, and for smaller vials of the medication to facilitate more precise dosing. Such changes would ensure that adverse events are minimized and that the children with aHUS who are treated with eculizumab experience an optimal clinical response.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07